Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, MA 02451, USA.
Discovery Chemistry Research and Technologies, Eli Lilly and Company, Indianapolis, IN 46285, USA.
Drug Discov Today. 2021 Mar;26(3):713-723. doi: 10.1016/j.drudis.2020.12.008. Epub 2020 Dec 14.
Drug-delivery technologies for modified drug release have been in existence for decades, but their utilization has been largely limited to post-launch efforts improving therapeutic outcomes. Recently, they have gained renewed importance because the pharmaceutical industry is steadily shifting to a more integrated discovery-development approach. In discovery, modulating target engagement via drug-delivery technologies can enable crucial pharmacological studies for building well-defined criteria for molecular design. In development, earlier implementation of delivery technologies can enhance the value of drug products through reduced dosing frequency and improved tolerability and/or safety profile, thereby leading to better adherence and therapeutic effectiveness.
药物传递技术已经存在了几十年，用于修饰药物释放，但它们的应用主要局限于上市后改善治疗效果的努力。最近，它们重新受到重视，因为制药行业正在稳步转向更集成的发现-开发方法。在发现阶段，通过药物传递技术调节靶标结合，可以为建立明确的分子设计标准进行关键的药理学研究。在开发阶段，更早地实施传递技术可以通过减少给药频率、提高耐受性和/或安全性来提高药物产品的价值，从而提高患者的依从性和治疗效果。
